Trial Details

COMPLETED
Basic Information
Clinical ID c682
Identifier NCT00032305
Trial Title Research Study in Patients With Severe Ulcerative Colitis
Trial URL Visit Original Page
Study Information
Study Results

NO
Conditions Ulcerative Colitis
Interventions DRUG: Visilizumab
Participant Information
Sponsor Facet Biotech
City Los Angeles
Country/Region United States
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE2|PHASE3
Time Information
Start Date 2025-03-02
Primary Completion Date 2025-11-05
Completion Date 2025-11-05